ClinicalTrials.gg
CompletedNCT00195481Updated Dec 28, 2007

Study Evaluating Sirolimus in Kidney Transplant Recipients in India

A Phase 4 interventional study of Rapamune in Kidney Failure and Graft vs Host Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 5 sites in India. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2007-12-28.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.

Enrollment
5th of 16
100 · median 63
Started
2004
with 1 other
Phase 4
6 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
7 of 16
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 5th largest by enrollment, is one of 2 that started in 2004, is one of 6 in phase 4, and was the 5th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing sirolimus in Renal Insufficiency as a file.
02

Study summary

To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.

03

Conditions studied

  • Kidney Failure
  • Graft vs Host Disease

Keywords

  • Kidney
  • Transplant
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients in End Stage Renal Disease who are above 13 years of age and weigh more than 40 kilograms.
  • Patients scheduled to receive a kidney from a cadaveric donor, from a living unrelated donor or from a living related donor.

Exclusion criteria

Exclusion Criteria:

  • Evidence of major infections at the time of sirolimus administration
  • Use of any drug or treatment up to 4 weeks prior to enrolling in the study and during the treatment phase.
  • Females who are pregnant, breast feeding or in reproductive age group and not using a medically acceptable form of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety evaluation

07

Study locations

5 sites
  • Bangalore, Karnataka 566 006, India
  • Bangalore, Karnataka 566 018, India
  • Saket, South Delhi, India
  • Chennai, Tamil Nadu 600 004, India
  • New Delhi, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Apr 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Last update
Dec 28, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195481
First posted
Sep 19, 2005
Start date
Apr 2004
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Dec 28, 2007

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion